|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0038477,
umls-concept:C0052323,
umls-concept:C0205549,
umls-concept:C0220781,
umls-concept:C0678594,
umls-concept:C1328650,
umls-concept:C1519249,
umls-concept:C1527178,
umls-concept:C1705938,
umls-concept:C1707689,
umls-concept:C1883254,
umls-concept:C2267054
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2000-2-28
|
|
pubmed:abstractText |
A series of arginine aldehyde inhibitors was designed as transition state (TS) analogues based on the known factor Xa specific substrate Cbz-D-Arg-Gly-Arg-pNA. BnSO2-(D)Arg-Gly-Arg-H (20) was found to be the most potent and selective inhibitor of factor Xa and prothrombinase activity in this series.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0960-894X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
3
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
13-6
|
|
pubmed:dateRevised |
2000-12-18
|
|
pubmed:meshHeading |
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Design, synthesis and structure-activity relationship of a series of arginine aldehyde factor Xa inhibitors. Part 1: structures based on the (D)-Arg-Gly-Arg tripeptide sequence.
|
|
pubmed:affiliation |
COR Therapeutics, Inc., South San Francisco, CA 94080, USA.
|
|
pubmed:publicationType |
Journal Article
|
